Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers, announced the licensing of a Granzyme B-targeted agent for PET imaging applications from MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA).